The findings of the study challenge concerns that exposure therapy may worsen symptoms in patients with PTSD, particularly when comorbid SUD is present.
The prevalence of acute posttraumatic stress symptoms in the study population was 4.6%, ranging from 4.4% in healthcare workers to 518.4% in the high-risk general population.
The Food and Drug Administration (FDA) has granted Fast Track designation to BNC210 (Bionomics Limited) for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders.
Among patients who received stellate ganglion block (n=74), the adjusted mean CAP-5 total symptom severity score change from baseline was -12.6 points (95% CI, -15.5, -9.7 points) vs -6.1 points (95% CI, -9.8, -2.3 points) for those who received sham treatment.
The long-term benefits of pharmacologic treatments were inferior to those of psychotherapeutic and combined treatments across 6 randomized clinical trials reviewed by investigators.
A machine learning algorithm trained on electroencephalographic coherence can predict transcranial magnetic stimulation treatment outcome for patients with major depressive disorder and posttraumatic stress disorder.
